Genmab CEO eyes big opportunities in global biotech downswing

New guidelines from the US Food and Drug Administration and the continued downswing within the biotech industry at large provide a range of new opportunities for Danish biotech firm Genmab, says CEO Jan van de Winkel.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

The global biotech industry’s battering on the stock market in recent months doesn’t have to be all bad news, says Jan van de Winkel, the CEO of Danish biotech firm Genmab, which has also been impacted on the stock exchange.

”The opportunities are great for a company like Genmab. We have a very robust cash holding, our earnings are growing and we have been profitable for nine years in a row,” he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs